← USPTO Patent Grants

Nuclease-mediated genome editing of primary cells and related kits

Grant US12584149B2 Kind: B2 Mar 24, 2026

Assignee

The Board of Trustees of the Leland Stanford Junior University

Inventors

Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus

Abstract

In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.

CPC Classifications

C12N 15/907 C12N 5/0647 A61K 31/7115 A61K 35/28

Filing Date

2022-12-05

Application No.

18074781

Claims

44